Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors
- 15 August 2009
- journal article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry
- Vol. 17 (16), 5974-5982
- https://doi.org/10.1016/j.bmc.2009.06.063
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Survivin as a universal tumor antigen for novel cancer immunotherapy: functions of a killer clone.Cancer Biology & Therapy, 2008
- Discovery of a novel small molecule binding site of human survivinBioorganic & Medicinal Chemistry Letters, 2007
- Identification and structure–activity relationships of substituted pyridones as inhibitors of Pim-1 kinaseBioorganic & Medicinal Chemistry Letters, 2007
- Cyclic nucleotide phosphodiesterase (PDE) inhibitors: novel therapeutic agents for progressive renal disease.2007
- Characterization of phosphodiesterase 3 in human malignant melanoma cell line.2003
- Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.2002
- Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells.2001
- Phosphodiesterase 3 as a potential target for therapy of malignant tumors in the submandibular glandAnti-Cancer Drugs, 2001
- Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1.2000
- Structural basis for phosphoserine-proline recognition by group IV WW domains.Nature Structural & Molecular Biology, 2000